Inhibition of telomerase activity by dominant-negative hTERT retards the growth of breast cancer cells

@article{Rao2014InhibitionOT,
  title={Inhibition of telomerase activity by dominant-negative hTERT retards the growth of breast cancer cells},
  author={Yaojian Rao and Wei Xiong and Huijuan Liu and C X Jia and Hong-xing Zhang and Zesheng Cui and Ya Qing Zhang and Jiawei Cui},
  journal={Breast Cancer},
  year={2014},
  volume={23},
  pages={216-223}
}
BackgroundTelomerase, a ribonucleoprotein enzyme mainly consisted of a catalytic protein subunit human telomerase reverse transcriptase (hTERT) and a human telomerase RNA component, is responsible for maintaining telomeres. Telomerase over-expression correlates significantly with tumors and is a prognostic marker. However, telomerase over-expression in breast cancers and the effect of telomerase inhibition as a candidate cancer therapy are unknown.MethodsWe used the dominant-negative mutant of… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 28 REFERENCES

Anticancer therapy targeting telomeres and telomerase : current status.

  • BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
  • 2007
VIEW 1 EXCERPT

Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2006
VIEW 1 EXCERPT